RxDoctor Payments Data

Gerard Boynton, MD

Family Medicine · Corpus Christi, TXNPI 1902914179

Payments from drug & device makers

$953in general payments, 2019–2025

Across 24 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$435
  • Actelion Pharmaceuticals US, Inc.$146
  • Lilly USA, LLC$89
  • Eisai Inc.$75
  • Vivus LLC$60
  • GSK$54
  • plus $94 from 4 others

What the payments were for

  • Food & beverage$953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$953 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$88,668
Medicare patients
226
Services billed
5,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide107$136,991
EliquisApixaban100$94,100
MounjaroTirzepatide49$52,796
Repatha SureclickEvolocumab64$38,559
OzempicSemaglutide24$34,280
XareltoRivaroxaban26$23,487
Praluent PenAlirocumab17$13,332
LinzessLinaclotide17$13,073
VascepaIcosapent Ethyl17$12,143
MyrbetriqMirabegron19$12,125
LivaloPitavastatin Calcium17$9,437
Icosapent Ethyl22$7,565
Dexlansoprazole DrDexlansoprazole34$6,509
Levothyroxine Sodium384$4,699
SymbicortBudesonide/Formoterol Fumarate11$4,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$89$189,787156 claims
AbbVieLinzess, Synthroid, Armour Thyroid$14$17,55183 claims
Kowa Pharmaceuticals America, Inc.Livalo$16$9,43717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →